Asadirad: Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial

Asadirad, 60 patient curcumin late treatment RCT: 26% lower mortality [p=0.74], 50% lower progression [p=0.47], and 45% improved recovery [p=0.09] https://c19p.org/asadirad

copied to clipboard

Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial

Asadirad et al., Phytotherapy Research, doi:10.1002/ptr.7375

17 Jan 2022 Source PDF Share Tweet

RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days.

Important missing comments or errors? Let us know.

risk of death, 25.9% lower, RR 0.74, p = 0.74, treatment 5 of 27 (18.5%), control 6 of 24 (25.0%), NNT 15, excluding patients that stopped treatment due to progression - 3 for curcumin and 6 for control.

risk of progression, 50.0% lower, RR 0.50, p = 0.47, treatment 3 of 30 (10.0%), control 6 of 30 (20.0%), NNT 10.0.

risk of unresolved fever, 45.3% lower, RR 0.55, p = 0.09, treatment 8 of 27 (29.6%), control 13 of 24 (54.2%), NNT 4.1.

risk of unresolved dyspnea, 28.9% lower, RR 0.71, p = 0.72, treatment 4 of 27 (14.8%), control 5 of 24 (20.8%), NNT 17.

risk of unresolved cough, 40.7% lower, RR 0.59, p = 0.36, treatment 6 of 27 (22.2%), control 9 of 24 (37.5%), NNT 6.5.

risk of O2 <92%, 36.5% lower, RR 0.63, p = 0.51, treatment 5 of 27 (18.5%), control 7 of 24 (29.2%), NNT 9.4.

risk of O2 <97%, 20.0% lower, RR 0.80, p = 0.21, treatment 18 of 27 (66.7%), control 20 of 24 (83.3%), NNT 6.0.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Asadirad et al., 17 Jan 2022, Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 7 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Curcumin All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit